查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1529698

類風濕性關節炎治療市場規模、佔有率、趨勢分析報告：按分子、銷售管道、地區、細分市場預測，2024-2030

Rheumatoid Arthritis Therapeutics Market Size, Share & Trends Analysis Report By Molecule (Pharmaceuticals, Biopharmaceuticals), By Sales Channel (Prescription, OTC), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

類風濕性關節炎治療市場的成長與趨勢：

根據Grand View Research, Inc.的最新研究，預計到2030年，全球類風濕性關節炎治療市場規模將達363.9億美元，2024年至2030年複合年成長率為5.93%。

預測期內複合年成長率將為 4.6%。推動市場的主要趨勢包括新型生技藥品的可用性、潛在臨床候選藥物數量的增加以及人口老化的加劇。因此，更安全藥物的供應和意識的提高預計將促進類類風濕性關節炎治療市場的成長。

類風濕性關節炎影響著世界上約 1% 的人口。這種疾病有多種症狀，包括關節疼痛、腫脹和僵硬，通常伴隨慢性疼痛和無法進行日常活動。隨著時間的推移，這種疾病會干擾患者的運動能力並導致關節永久性損傷。如果不及時治療，這種疾病可能會導致運動障礙和關節關節重建手術的風險。

該疾病盛行率的不斷上升、生技藥品和生物學名藥的出現以及明確的監管指南將為市場提供動力。根據關節炎基金會的數據，美國65 歲以下的人中有 64% 可能患有關節炎。據估計，已開發地區對疾病緩解治療的認知不斷提高以及醫療保健成本不斷上升將推動收益成長。

目前治療類風濕性關節炎的藥物包括JAK抑制劑和IL-6拮抗劑等新型生技藥品，以及非類固醇消炎劑（NSAID）和皮質類固醇等學名藥，這些藥物在已開發國家被廣泛使用。Infliximab、Adalimumab生物相似藥等新產品的上市預計將利好市場。此外，禮來公司的 Olumiant 和艾伯維公司的 Upadacitinib 也有望降低疾病復發的可能性。

類風濕性關節炎治療市場報告亮點

  • 生物製藥領域引領市場，2023年佔全球銷售額的88.73%。生物製藥是從生物資源製造、提取或合成的高分子藥物。
  • 處方藥以2023年89.64%的市場佔有率領先市場。隨著風濕症醫師諮詢的增加，處方藥領域預計將在預測期內保持在類風濕性關節炎治療市場的主導地位。
  • 2023年北美類風濕性關節炎治療市佔52.31%。由於人口結構的變化、醫學研究的進步、監管的變化以及對個人化醫療的日益重視，該區域市場持續成長和發展。
  • 在類類風濕性關節炎盛行率不斷上升、醫療基礎設施改善以及治療選擇不斷進步的推動下，亞太地區類類風濕性關節炎治療市場正在顯著成長。

目錄

第1章調查方法和範圍

第2章執行概述

第3章類風濕性關節炎治療市場變數、趨勢與範圍

  • 類風濕性關節炎治療市場的系統展望
    • 母市場展望
    • 輔助市場展望 - 骨關節炎治療市場
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 類風濕性關節炎治療市場分析工具
    • 波特五力分析
    • PESTLE分析

第 4 章 2018-2030 年類風濕性關節炎治療市場分析（按分子）（百萬美元）

  • 類風濕性關節炎治療：分子變異分析
  • 類風濕性關節炎治療市場分析：依分子分類
    • 生物製藥
    • 藥品

第 5 章類風濕性關節炎治療市場分析，按銷售管道，2018-2030 年（百萬美元）

  • 類風濕性關節炎治療：銷售管道波動分析
  • 類風濕性關節炎治療市場分析：依銷售管道
    • 處方藥
    • 非處方藥 (OTC)

第6章類風濕性關節炎治療市場：按分子和銷售管道分類的區域估計和趨勢分析

  • 類風濕性關節炎治療市場：區域展望
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第7章 競爭格局

  • 市場參與企業分類
  • 主要企業簡介
    • AbbVie, Inc.
    • Boehringer Ingelheim International GmbH
    • Novartis AG
    • Regeneron Pharmaceuticals Inc.
    • Pfizer, Inc.
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd.
    • UCB SA
    • Johnson &Johnson Services, Inc.
    • AG Amgen, Inc.
    • Lilly（Eli Lilly and Company）
Product Code: GVR-2-68038-313-3

Rheumatoid Arthritis Therapeutics Market Growth & Trends:

The global rheumatoid arthritis therapeutics market size is expected to reach USD 36.39 billion by 2030, expanding at a CAGR of 5.93% from 2024 to 2030, according to a new study by Grand View Research, Inc. expanding at a CAGR of 4.6% during the forecast period. Some of the key trends driving the market are availability of novel biologics, increase in potential clinical pipeline candidates, and rise in aging population. Thus, growing availability and awareness of safer drugs are projected to escalate rheumatoid arthritis drugs market growth.

Rheumatoid arthritis affects approximately 1% of the global population. The condition has different symptoms such as joint pain, swelling, and stiffness, which are generally accompanied by chronic pain and inability to perform daily activities. Over a prolonged period, this disorder can hamper a patient's mobility and can lead to permanent joint damage. If left untreated, this disorder can lead to mobility impairment and risk of joint replacement.

Growing prevalence of the disease, presence of biologics & biosimilars, and well-defined regulatory guidelines are poised to provide a fillip to the market. According to the Arthritis Foundation, 64% of the population within the age group of 65 is likely to suffer from arthritis in U.S. Increasing awareness regarding disease remittance therapies and rising healthcare expenditure in developed regions are estimated to promote revenue growth.

Current treatment for rheumatoid arthritis includes generic pharmaceuticals such as NSAIDs and corticosteroids along with novel biologics such as JAK inhibitors and IL-6 antagonists, which are widely used in developed countries due to their high effectiveness. New product launches such as Infliximab and Adalimumab biosimilars are anticipated to work in favor of the market. Moreover, Eli Lilly's Olumiant and AbbVie's Upadacitinib are expected to cut down chances of disease remittance.

Rheumatoid Arthritis Therapeutics Market Report Highlights:

  • Biopharmaceuticals segment led the market and accounted for 88.73% of the global revenue in 2023. Biopharmaceuticals are large-molecule drugs that are manufactured, extracted, and synthesized from biological sources.
  • Prescription led the market with a market share of 89.64% in 2023. As rheumatologist consultations rise, the prescription segment is expected to remain dominant in the market for rheumatoid arthritis medications over the forecast period.
  • North America rheumatoid arthritis therapeutics market accounted for 52.31% share in 2023. The regional market continues to grow and evolve, driven by demographic shifts, advancements in medical research, regulatory changes, and an increasing emphasis on personalized healthcare.
  • The Asia Pacific rheumatoid arthritis therapeutics market is experiencing significant growth, driven by the increasing prevalence of rheumatoid arthritis, improving healthcare infrastructure, and advancements in treatment options.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Molecule
    • 1.2.2. Sales channel
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Molecule and Sales Channel Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Rheumatoid Arthritis Therapeutics Market Variables, Trends, and Scope

  • 3.1. Rheumatoid Arthritis Therapeutics Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary market outlook - Osteoarthritis Therapeutics Market
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing prevalence of rheumatoid arthritis
      • 3.2.1.2. Launch of novel therapeutic agents
      • 3.2.1.3. Shift in treatment from the relief of symptoms to targeted therapy
      • 3.2.1.4. Favorable reimbursement policies
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High cost of rheumatoid arthritis therapeutic drugs
      • 3.2.2.2. Side effects and adverse reactions
  • 3.3. Rheumatoid Arthritis Therapeutics Market Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTLE Analysis

Chapter 4. Rheumatoid Arthritis Therapeutics Market Analysis, by Molecule, 2018 - 2030 (USD Million)

  • 4.1. Rheumatoid Arthritis Therapeutics: Molecule Movement Analysis
  • 4.2. Rheumatoid Arthritis Therapeutics Market Analysis, by Molecule Market (USD Million)
    • 4.2.1. Biopharmaceuticals
      • 4.2.1.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.2.1.2. Biologics
      • 4.2.1.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.2.1.2.2. TNF-a antagonists
      • 4.2.1.2.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.2.1.2.3. T-cell inhibitors
      • 4.2.1.2.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.2.1.2.4. CD20 antigen
      • 4.2.1.2.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.2.1.2.5. JAK inhibitors
      • 4.2.1.2.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.2.1.2.6. anti-IL6 biologics
      • 4.2.1.2.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.2.1.3. Biosimilars
      • 4.2.1.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.2.1.3.2. CD20 antigen
      • 4.2.1.3.3. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.2.1.3.4. TNF-a antagonists
      • 4.2.1.3.5. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.2.2. Pharmaceuticals
      • 4.2.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.2.2.2. NSAIDs
      • 4.2.2.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.2.2.3. Analgesics
      • 4.2.2.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.2.2.4. DMARDs
      • 4.2.2.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.2.2.5. Glucocorticoids
      • 4.2.2.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Rheumatoid Arthritis Therapeutics Market Analysis, by Sales Channel, 2018 - 2030 (USD Million)

  • 5.1. Rheumatoid Arthritis Therapeutics: Sales Channel Movement Analysis
  • 5.2. Rheumatoid Arthritis Therapeutics Market Analysis, by Sales Channel Market (USD Million)
    • 5.2.1. Prescription
      • 5.2.1.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.2.2. Over-the-Counter (OTC)
      • 5.2.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Rheumatoid Arthritis Therapeutics Market: Regional Estimates and Trend Analysis by Molecule, by Sales Channel

  • 6.1. Rheumatoid Arthritis Therapeutics Market: Regional Outlook
  • 6.2. North America
    • 6.2.1. North America Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.2. U.S.
      • 6.2.2.1. Key Country Dynamics
      • 6.2.2.2. Target Disease Prevalence
      • 6.2.2.3. U.S. Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.2.2.4. Competitive/Market Scenario
      • 6.2.2.5. Regulatory Framework
      • 6.2.2.6. Reimbursement scenario
    • 6.2.3. Canada
      • 6.2.3.1. Key Country Dynamics
      • 6.2.3.2. Target Disease Prevalence
      • 6.2.3.3. Canada Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.2.3.4. Competitive/Market Scenario
      • 6.2.3.5. Regulatory Framework
      • 6.2.3.6. Reimbursement Scenario
    • 6.2.4. Mexico
      • 6.2.4.1. Key Country Dynamics
      • 6.2.4.2. Target Disease Prevalence
      • 6.2.4.3. Mexico Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.2.4.4. Competitive/Market Scenario
      • 6.2.4.5. Regulatory Framework
      • 6.2.4.6. Reimbursement Scenario
  • 6.3. Europe
    • 6.3.1. Europe Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.2. UK
      • 6.3.2.1. Key Country Dynamics
      • 6.3.2.2. Target Disease Prevalence
      • 6.3.2.3. UK Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.3.2.4. Competitive/Market Scenario
      • 6.3.2.5. Regulatory Framework
      • 6.3.2.6. Reimbursement Scenario
    • 6.3.3. Germany
      • 6.3.3.1. Key Country Dynamics
      • 6.3.3.2. Target Disease Prevalence
      • 6.3.3.3. Germany Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.3.3.4. Competitive/Market Scenario
      • 6.3.3.5. Regulatory Framework
      • 6.3.3.6. Reimbursement Scenario
    • 6.3.4. France
      • 6.3.4.1. Key Country Dynamics
      • 6.3.4.2. Target Disease Prevalence
      • 6.3.4.3. France Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.3.4.4. Competitive/Market Scenario
      • 6.3.4.5. Regulatory Framework
      • 6.3.4.6. Reimbursement Scenario
    • 6.3.5. Spain
      • 6.3.5.1. Key Country Dynamics
      • 6.3.5.2. Target Disease Prevalence
      • 6.3.5.3. Spain Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.3.5.4. Competitive/Market Scenario
      • 6.3.5.5. Regulatory Framework
      • 6.3.5.6. Reimbursement Scenario
    • 6.3.6. Italy
      • 6.3.6.1. Key Country Dynamics
      • 6.3.6.2. Target Disease Prevalence
      • 6.3.6.3. Italy Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.3.6.4. Competitive/Market Scenario
      • 6.3.6.5. Regulatory Framework
      • 6.3.6.6. Reimbursement Scenario
    • 6.3.7. Denmark
      • 6.3.7.1. Key Country Dynamics
      • 6.3.7.2. Target Disease Prevalence
      • 6.3.7.3. Denmark Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.3.7.4. Competitive/Market Scenario
      • 6.3.7.5. Regulatory Framework
      • 6.3.7.6. Reimbursement Scenario
    • 6.3.8. Sweden
      • 6.3.8.1. Key Country Dynamics
      • 6.3.8.2. Target Disease Prevalence
      • 6.3.8.3. Sweden Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.3.8.4. Competitive/Market Scenario
      • 6.3.8.5. Regulatory Framework
      • 6.3.8.6. Reimbursement Scenario
    • 6.3.9. 6.3.9 Norway
      • 6.3.9.1. Key Country Dynamics
      • 6.3.9.2. Target Disease Prevalence
      • 6.3.9.3. Norway Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.3.9.4. Competitive/Market Scenario
      • 6.3.9.5. Regulatory Framework
      • 6.3.9.6. Reimbursement Scenario
      • 6.3.9.7. Rest of Europe Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Rheumatoid Arthritis Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. Japan
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Prevalence
      • 6.4.2.3. Japan Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.4.2.4. Competitive/Market Scenario
      • 6.4.2.5. Regulatory Framework
      • 6.4.2.6. Reimbursement Scenario
    • 6.4.3. China
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. China Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.4.3.4. Competitive/Market Scenario
      • 6.4.3.5. Regulatory Framework
      • 6.4.3.6. Reimbursement Scenario
    • 6.4.4. India
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. India Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.4.4.4. Competitive/Market Scenario
      • 6.4.4.5. Regulatory Framework
      • 6.4.4.6. Reimbursement Scenario
    • 6.4.5. Australia
      • 6.4.5.1. Key Country Dynamics
      • 6.4.5.2. Target Disease Prevalence
      • 6.4.5.3. Australia Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.4.5.4. Competitive/Market Scenario
      • 6.4.5.5. Regulatory Framework
      • 6.4.5.6. Reimbursement Scenario
    • 6.4.6. Thailand
      • 6.4.6.1. Key Country Dynamics
      • 6.4.6.2. Target Disease Prevalence
      • 6.4.6.3. Thailand Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.4.6.4. Competitive/Market Scenario
      • 6.4.6.5. Regulatory Framework
      • 6.4.6.6. Reimbursement Scenario
    • 6.4.7. South Korea
      • 6.4.7.1. Key Country Dynamics
      • 6.4.7.2. Target Disease Prevalence
      • 6.4.7.3. South Korea Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.4.7.4. Competitive/Market Scenario
      • 6.4.7.5. Regulatory Framework
      • 6.4.7.6. Reimbursement Scenario
      • 6.4.7.7. Rest of Asia Pacific Rheumatoid Arthritis Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Latin America
    • 6.5.1. Latin America Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. Brazil
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Prevalence
      • 6.5.2.3. Brazil Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.5.2.4. Competitive/Market Scenario
      • 6.5.2.5. Regulatory Framework
      • 6.5.2.6. Reimbursement Scenario
    • 6.5.3. Argentina
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Argentina Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.5.3.4. Competitive/Market Scenario
      • 6.5.3.5. Regulatory Framework
      • 6.5.3.6. Reimbursement Scenario
      • 6.5.3.7. Rest of Latin America Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. MEA
    • 6.6.1. MEA Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. South Africa
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Prevalence
      • 6.6.2.3. South Africa Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.6.2.4. Competitive/Market Scenario
      • 6.6.2.5. Regulatory Framework
      • 6.6.2.6. Reimbursement Scenario
    • 6.6.3. Saudi Arabia
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Saudi Arabia Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.6.3.4. Competitive/Market Scenario
      • 6.6.3.5. Regulatory Framework
      • 6.6.3.6. Reimbursement Scenario
    • 6.6.4. UAE
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. UAE Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.6.4.4. Competitive/Market Scenario
      • 6.6.4.5. Regulatory Framework
      • 6.6.4.6. Reimbursement Scenario
    • 6.6.5. Kuwait
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Kuwait Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 6.6.5.4. Competitive/Market Scenario
      • 6.6.5.5. Regulatory Framework
      • 6.6.5.6. Reimbursement Scenario
    • 6.6.6. Rest of MEA Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Market Participant Categorization
  • 7.2. Key Company Profiles
    • 7.2.1. AbbVie, Inc.
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. Boehringer Ingelheim International GmbH
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Novartis AG
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Regeneron Pharmaceuticals Inc.
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. Pfizer, Inc.
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. Bristol-Myers Squibb Company
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. F. Hoffmann-La Roche Ltd.
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. UCB S.A.
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. Johnson & Johnson Services, Inc.
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Product benchmarking
      • 7.2.9.4. Strategic initiatives
    • 7.2.10. AG Amgen, Inc.
      • 7.2.10.1. Company overview
      • 7.2.10.2. Financial performance
      • 7.2.10.3. Product benchmarking
      • 7.2.10.4. Strategic initiatives
    • 7.2.11. Lilly (Eli Lilly and Company)
      • 7.2.11.1. Company overview
      • 7.2.11.2. Financial performance
      • 7.2.11.3. Product benchmarking
      • 7.2.11.4. Strategic initiatives

List of Tables

  • Table 1. List of Secondary Sources
  • Table 2. List of Abbreviations
  • Table 3. Global rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 4. Global rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 5. North America rheumatoid arthritis therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 6. North America rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 7. North America rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 8. U.S. rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 9. U.S. rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 10. Canada rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 11. Canada rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 12. Mexico rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 13. Mexico rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 14. Europe rheumatoid arthritis therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 15. Europe rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 16. Europe rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 17. UK rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 18. UK rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 19. Germany rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 20. Germany rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 21. France rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 22. France rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 23. Italy rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 24. Italy rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 25. Spain rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 26. Spain rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 27. Norway rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 28. Norway rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 29. Sweden rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 30. Sweden rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 31. Denmark rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 32. Denmark rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 33. Asia Pacific rheumatoid arthritis therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 34. Asia Pacific rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 35. Asia Pacific rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 36. Japan rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 37. Japan rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 38. China rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 39. China rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 40. India rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 41. India rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 42. Australia rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 43. Australia rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 44. South Korea rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 45. South Korea rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 46. Thailand rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 47. Thailand rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 48. Latin America rheumatoid arthritis therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 49. Latin America rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 50. Latin America rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 51. Brazil rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 52. Brazil rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 53. Argentina rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 54. Argentina rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 55. Middle East & Africa rheumatoid arthritis therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 56. Middle East & Africa rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 57. Middle East & Africa rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 58. South Africa rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 59. South Africa rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 60. Saudi Arabia rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 61. Saudi Arabia rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 62. UAE rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 63. UAE rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
  • Table 64. Kuwait rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
  • Table 65. Kuwait rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Rheumatoid arthritis therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Molecule and sales channel segment snapshot
  • Fig. 11 Competitive landscape snapshot
  • Fig. 12 Global Pharmaceutical Market, (USD billion)
  • Fig. 13 Market dynamics
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 PESTLE analysis
  • Fig. 16 Rheumatoid arthritis therapeutics: Molecule outlook and key takeaways
  • Fig. 17 Rheumatoid arthritis therapeutics market: Molecule market movement analysis
  • Fig. 18 Biopharmaceuticals market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Biologics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 TNF-a antagonists market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 T-cell inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 CD20 antigen market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 JAK inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Anti-IL6 biologics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Biosimilars market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 CD20 antigen market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 TNF-a antagonists market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Pharmaceuticals market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 NSAIDs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Analgesics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 DMARDs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Glucocorticoids market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Rheumatoid arthritis therapeutics: Sales channel outlook and key takeaways
  • Fig. 34 Rheumatoid arthritis therapeutics market: Sales channel market movement analysis
  • Fig. 35 Prescription market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Over-the-Counter (OTC) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Rheumatoid arthritis therapeutics market revenue, by region, 2023 & 2030 (USD Million)
  • Fig. 38 Regional marketplace: Key takeaways
  • Fig. 39 Regional marketplace: Key takeaways
  • Fig. 40 North America rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Key country dynamics
  • Fig. 42 U.S. rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 U.S. healthcare system: money flow
  • Fig. 44 Key country dynamics
  • Fig. 45 Canada rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Drug pricing
  • Fig. 47 Key country dynamics
  • Fig. 48 Mexico rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Regulatory framework
  • Fig. 50 Europe rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 UK rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Key country dynamics
  • Fig. 54 Germany rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 France rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Spain rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Key country dynamics
  • Fig. 60 Italy rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 Denmark rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Key country dynamics
  • Fig. 64 Sweden rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Key country dynamics
  • Fig. 66 Norway rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Rest of Europe rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Asia Pacific rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Key country dynamics
  • Fig. 70 Japan rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Key country dynamics
  • Fig. 72 China rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 China regulatory details
  • Fig. 74 India rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Key country dynamics
  • Fig. 76 Australia rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Key country dynamics
  • Fig. 78 Thailand rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Key country dynamics
  • Fig. 80 South Korea rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 South Korea reimbursement scenario
  • Fig. 82 Rest of Asia Pacific rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Latin America rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 Brazil rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Brazil regulation details
  • Fig. 87 Brazil reimbursement scenario
  • Fig. 88 Key country dynamics
  • Fig. 89 Argentina rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 Argentina regulatory framework
  • Fig. 91 Rest of Latin America rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 Key country dynamics
  • Fig. 93 South Africa rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 94 Key country dynamics
  • Fig. 95 Saudi Arabia rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 96 Key country dynamics
  • Fig. 97 UAE rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 98 Key country dynamics
  • Fig. 99 Kuwait rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2023 (USD Million)
  • Fig. 100 Rest of MEA rheumatoid arthritis therapeutics market estimates and forecasts,
  • Fig. 101 Company/competition categorization
  • Fig. 102 Company market share analysis, 2023
  • Fig. 103 Strategy mapping